Proteomics in cardiovascular diseases: unveiling sex and gender differences in the era of precision medicine

Roberta Baetta; Marta Pontremoli; Alma Martinez Fernandez; Corinne M. Spickett; Cristina Banfi

doi:10.1016/j.jprot.2017.11.012

Proteomics in cardiovascular diseases: unveiling sex and gender differences in the era of precision medicine

Roberta Baetta, Marta Pontremoli, Alma Martinez Fernandez, Corinne M. Spickett, Cristina Banfi

Research output: Contribution to journal › Article › peer-review

Abstract

Cardiovascular diseases (CVDs) represent the most important cause of mortality in women and in men. Contrary to the long-standing notion that the effects of the major risk factors on CVD outcomes are the same in both sexes, recent evidence recognizes new, potentially independent, sex/gender-related risk factors for CVDs, and sex/gender-differences in the clinical presentation of CVDs have been demonstrated. Furthermore, some therapeutic options may not be equally effective and safe in men and women. In this context, proteomics offers an extremely useful and versatile analytical platform for biomedical researches that expand from the screening of early diagnostic and prognostic biomarkers to the investigation of the molecular mechanisms underlying CDVs. In this review, we summarized the current applications of proteomics in the cardiovascular field, with emphasis on sex and gender-related differences in CVDs.

Significance

Increasing evidence supports the profound effect of sex and gender on cardiovascular physio-pathology and the response to drugs. A clear understanding of the mechanisms underlying sexual dimorphisms in CVDs would not only improve our knowledge of the etiology of these diseases, but could also inform health policy makers and guideline committees in tailoring specific interventions for the prevention, treatment and management of CVDs in both men and women.

Original language	English
Pages (from-to)	62-76
Number of pages	15
Journal	Journal of Proteomics
Volume	173
Early online date	24 Nov 2017
DOIs	https://doi.org/10.1016/j.jprot.2017.11.012
Publication status	Published - 20 Feb 2018

Bibliographical note

© 2017, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/

Funding: European Union’s Horizon 2020 research and innovation
programme under the Marie Sklodowska-Curie grant agreement number 675132

Keywords

Sex differences
Gender
Cardiovascular disease
Risk factors
Oxidative stress
Proteomics

Access to Document

10.1016/j.jprot.2017.11.012

Proteomics in cardiovascular diseases Unveiling sex and gender
© 2017, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/
Accepted author manuscript, 1.21 MBLicence: CC BY-NC-ND 3.0

http://linkinghub.elsevier.com/retrieve/pii/S1874391917303925

Cite this

@article{77713ce3a57c444c8d2f68d8de01968e,

title = "Proteomics in cardiovascular diseases: unveiling sex and gender differences in the era of precision medicine",

abstract = "Cardiovascular diseases (CVDs) represent the most important cause of mortality in women and in men. Contrary to the long-standing notion that the effects of the major risk factors on CVD outcomes are the same in both sexes, recent evidence recognizes new, potentially independent, sex/gender-related risk factors for CVDs, and sex/gender-differences in the clinical presentation of CVDs have been demonstrated. Furthermore, some therapeutic options may not be equally effective and safe in men and women. In this context, proteomics offers an extremely useful and versatile analytical platform for biomedical researches that expand from the screening of early diagnostic and prognostic biomarkers to the investigation of the molecular mechanisms underlying CDVs. In this review, we summarized the current applications of proteomics in the cardiovascular field, with emphasis on sex and gender-related differences in CVDs.SignificanceIncreasing evidence supports the profound effect of sex and gender on cardiovascular physio-pathology and the response to drugs. A clear understanding of the mechanisms underlying sexual dimorphisms in CVDs would not only improve our knowledge of the etiology of these diseases, but could also inform health policy makers and guideline committees in tailoring specific interventions for the prevention, treatment and management of CVDs in both men and women.",

keywords = "Sex differences, Gender, Cardiovascular disease, Risk factors, Oxidative stress, Proteomics",

author = "Roberta Baetta and Marta Pontremoli and Fernandez, {Alma Martinez} and Spickett, {Corinne M.} and Cristina Banfi",

note = "{\textcopyright} 2017, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ Funding: European Union{\textquoteright}s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement number 675132",

year = "2018",

month = feb,

day = "20",

doi = "10.1016/j.jprot.2017.11.012",

language = "English",

volume = "173",

pages = "62--76",

journal = "Journal of Proteomics",

issn = "1874-3919",

publisher = "Elsevier",

}

TY - JOUR

T1 - Proteomics in cardiovascular diseases

T2 - unveiling sex and gender differences in the era of precision medicine

AU - Baetta, Roberta

AU - Pontremoli, Marta

AU - Fernandez, Alma Martinez

AU - Spickett, Corinne M.

AU - Banfi, Cristina

N1 - © 2017, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/ Funding: European Union’s Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement number 675132

PY - 2018/2/20

Y1 - 2018/2/20

N2 - Cardiovascular diseases (CVDs) represent the most important cause of mortality in women and in men. Contrary to the long-standing notion that the effects of the major risk factors on CVD outcomes are the same in both sexes, recent evidence recognizes new, potentially independent, sex/gender-related risk factors for CVDs, and sex/gender-differences in the clinical presentation of CVDs have been demonstrated. Furthermore, some therapeutic options may not be equally effective and safe in men and women. In this context, proteomics offers an extremely useful and versatile analytical platform for biomedical researches that expand from the screening of early diagnostic and prognostic biomarkers to the investigation of the molecular mechanisms underlying CDVs. In this review, we summarized the current applications of proteomics in the cardiovascular field, with emphasis on sex and gender-related differences in CVDs.SignificanceIncreasing evidence supports the profound effect of sex and gender on cardiovascular physio-pathology and the response to drugs. A clear understanding of the mechanisms underlying sexual dimorphisms in CVDs would not only improve our knowledge of the etiology of these diseases, but could also inform health policy makers and guideline committees in tailoring specific interventions for the prevention, treatment and management of CVDs in both men and women.

AB - Cardiovascular diseases (CVDs) represent the most important cause of mortality in women and in men. Contrary to the long-standing notion that the effects of the major risk factors on CVD outcomes are the same in both sexes, recent evidence recognizes new, potentially independent, sex/gender-related risk factors for CVDs, and sex/gender-differences in the clinical presentation of CVDs have been demonstrated. Furthermore, some therapeutic options may not be equally effective and safe in men and women. In this context, proteomics offers an extremely useful and versatile analytical platform for biomedical researches that expand from the screening of early diagnostic and prognostic biomarkers to the investigation of the molecular mechanisms underlying CDVs. In this review, we summarized the current applications of proteomics in the cardiovascular field, with emphasis on sex and gender-related differences in CVDs.SignificanceIncreasing evidence supports the profound effect of sex and gender on cardiovascular physio-pathology and the response to drugs. A clear understanding of the mechanisms underlying sexual dimorphisms in CVDs would not only improve our knowledge of the etiology of these diseases, but could also inform health policy makers and guideline committees in tailoring specific interventions for the prevention, treatment and management of CVDs in both men and women.

KW - Sex differences

KW - Gender

KW - Cardiovascular disease

KW - Risk factors

KW - Oxidative stress

KW - Proteomics

U2 - 10.1016/j.jprot.2017.11.012

DO - 10.1016/j.jprot.2017.11.012

M3 - Article

SN - 1874-3919

VL - 173

SP - 62

EP - 76

JO - Journal of Proteomics

JF - Journal of Proteomics

ER -

Proteomics in cardiovascular diseases: unveiling sex and gender differences in the era of precision medicine

Abstract

Bibliographical note

Keywords

Access to Document

Fingerprint

Cite this